The provincial bureau went to drug manufacturers for investigation

In order to conscientiously study and implement the spirit of the work report of the 20th National Congress of the Communist Party of China (CPC) “Strive to improve the resilience and safety level of the industrial chain supply chain”, implement the work requirements of the provincial conference to promote the development of strong industrial provinces, and further promote the high-quality development of the province’s bio pharmaceutical industry, on October 17, Zhang Guangwen, a party member and deputy director of the provincial bureau, went to the enterprise to carry out research, accompanied by relevant responsible personnel of the Pharmaceutical Production Department.

Vice Director Zhang Guangwen and his delegation successively came to Jiminxin Yaohu Production Base and Jiangxi Haoran Bio-pharma Co., Ltd., listened to the enterprise development report on the site, understood the progress of the enterprise construction project in detail, answered the doubts about the enterprise development on the site, and discussed the industrial development ideas and future innovation direction with relevant personnel of the enterprise.


Vice Director Zhang Guangwen pointed out that the first thing for enterprises is to strengthen innovation and breakthrough and master key technologies. We should improve the independence and controllability, shift the focus of development to the ability of independent innovation of products, and constantly improve the position of pharmaceutical manufacturers in the division of labor in the national biopharmaceutical industry. The second is to prevent risks in time to ensure quality safety. After transformation and upgrading, enterprises should adapt to the role change as soon as possible, put drug quality and safety management in the most important position, and effectively maintain the lifeline of drug production enterprise development. Third, we should make good use of policies and seize development opportunities. Enterprises should grasp the situation, keep an eye on the overall situation, make use of policies, seize opportunities, and transform the policy dividend into a strong driving force for enterprise development, so as to boost the high-quality development of the province’s bio pharmaceutical industry.

Jiangxi Haoran Bio-pharma Co., Ltd. will take this inspection as an opportunity to carefully sort out and summarize the guidance given by the research team and fully implement it.

Post time: Oct-17-2022